Genmab(GMAB) - 2025 Q1 - Quarterly Report

Genmab Announces Financial Results for the First Quarter of 2025 May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights "Our commitment to advancing our late-stage programs was reflected in the progress we made in the first quarter of the year. Both EPKINLY and Tivdak expanded their reach with approvals in additional territories and the updated Rina-S data presented at SGO reinforces its potential as a treatment option for patients with advanced ovarian cancer, ...